Recro Pharma, Inc. (REPH) |
| 2.09 -0.01 (-0.48%) 03-22 00:00 |
| Open: | 2.07 |
| High: | 2.14 |
| Low: | 2.0001 |
| Volume: | 137,536 |
| Market Cap: | 177(M) |
| PE Ratio: | -8.04 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 3.29 |
| 52w Low: | 1.38 |
Recro Pharma, Inc. operates as a contract development and manufacturing organization (CDMO), offering comprehensive services for the development, production, and packaging of diverse therapeutic dosage forms. The company primarily specializes in small molecule therapeutic development, serving both domestic U.S. and international clients. Its extensive capabilities encompass a wide array of formats, including oral solid doses, sterile injectable solutions, oral liquid preparations, tablets, topical formulations, liquid/powder-filled capsules, ophthalmic droppers, liposomal products, and nano/microparticles. Furthermore, Recro Pharma provides specialized services such as aseptic fill/finish, lyophilization (freeze-drying), final packaging, and logistics management. Originally founded as Recro Pharma I, Inc., the company underwent a name change to Recro Pharma, Inc. in August 2008. The organization was established in 2007 and is headquartered in Exton, Pennsylvania.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Wed, 21 Sep 2022
A New Pain Treatment Requires Accurate And Reliable Data - Clinical Leader
Mon, 21 Mar 2022
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation - GlobeNewswire
Wed, 19 Jan 2022
Recro Appoints Eduardo Uribe as Head of Quality - citybiz
Fri, 13 Aug 2021
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO - GlobeNewswire
Fri, 13 Aug 2021
Recro Acquires IRISYS - citybiz
Tue, 16 Apr 2019
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville - GlobeNewswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |